DF4 Connector System Post-Approval Study
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate long-term performance of the DF4 Connector System. This evaluation is based on the number of DF4 lead-related complications occurring during the study compared to the number of leads enrolled in the study. The DF4 systems will be followed for 5 years after implant. This study is required by FDA as a condition of approval of the DF4 Connector Systems. This study is conducted within Medtronic's post-market surveillance platform.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- DF4 Lead Related Complication Rate [Up to 5 Years]
To demonstrate that the complication-free probability is greater than 92.5% at five years post-implant for the high voltage DF4 lead
Secondary Outcome Measures
- Types of DF4 lead related events [Up to 5 years]
Number of DF4 lead related events grouped by type
- Bipolar pacing impedance (ohms) [5 years]
Summary statistics at 5 years post-implant will be reported.
- High voltage impedance (ohms) [5 years]
Summary statistics at 5 years post-implant will be reported
- Pacing threshold (volts) [5 years]
The pacing threshold is the minimum electrical stimulus needed to consistently depolarize the heart outside of the heart's refractory period. Summary statistics at 5 years post-implant will be reported.
- Sensing amplitude (millivolts) [5 years]
The amplitude of the intrinsic cardiac electrical signals detected by electrodes on the defibrillator lead will be summarized at 5 years post-implant.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
-
Subject is intended to be implanted or is within 30 days post-implant of a DF4 Connector System with a Medtronic DF4 lead used for a pacing, sensing and/or defibrillation application
Exclusion Criteria:
-
Subject who is, or will be inaccessible for follow-up at a study site
-
Subject with exclusion criteria required by local law (Europe, Central Asia [ECA] only)
-
Implant and follow-up data, including any adverse device effects and system modifications at implant through the time of enrollment are unavailable
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Birmingham | Alabama | United States | ||
2 | Anchorage | Alaska | United States | ||
3 | Gilbert | Arizona | United States | ||
4 | Scottsdale | Arizona | United States | ||
5 | Jonesboro | Arkansas | United States | ||
6 | Little Rock | Arkansas | United States | ||
7 | Bakersfield | California | United States | ||
8 | Chula Vista | California | United States | ||
9 | Rancho Mirage | California | United States | ||
10 | Salinas | California | United States | ||
11 | San Diego | California | United States | ||
12 | San Francisco | California | United States | ||
13 | Torrance | California | United States | ||
14 | Van Nuys | California | United States | ||
15 | Colorado Springs | Colorado | United States | ||
16 | Lakewood | Colorado | United States | ||
17 | Newark | Delaware | United States | ||
18 | Washington | District of Columbia | United States | ||
19 | Bradenton | Florida | United States | ||
20 | Clearwater | Florida | United States | ||
21 | Albany | Georgia | United States | ||
22 | Atlanta | Georgia | United States | ||
23 | Marietta | Georgia | United States | ||
24 | Indianapolis | Indiana | United States | ||
25 | Des Moines | Iowa | United States | ||
26 | Kansas City | Kansas | United States | ||
27 | Edgewood | Kentucky | United States | ||
28 | Louisville | Kentucky | United States | ||
29 | Baton Rouge | Louisiana | United States | ||
30 | Hyattsville | Maryland | United States | ||
31 | Takoma Park | Maryland | United States | ||
32 | Worcester | Massachusetts | United States | ||
33 | Lansing | Michigan | United States | ||
34 | Marquette | Michigan | United States | ||
35 | Robbinsdale | Minnesota | United States | ||
36 | Saint Louis Park | Minnesota | United States | ||
37 | Saint Paul | Minnesota | United States | ||
38 | Columbia | Missouri | United States | ||
39 | Kansas City | Missouri | United States | ||
40 | Saint Louis | Missouri | United States | ||
41 | Henderson | Nevada | United States | ||
42 | Morristown | New Jersey | United States | ||
43 | Albuquerque | New Mexico | United States | ||
44 | Garden City | New York | United States | ||
45 | Huntington | New York | United States | ||
46 | New York | New York | United States | ||
47 | Poughkeepsie | New York | United States | ||
48 | Utica | New York | United States | ||
49 | Durham | North Carolina | United States | ||
50 | Raleigh | North Carolina | United States | ||
51 | Winston-Salem | North Carolina | United States | ||
52 | Akron | Ohio | United States | ||
53 | Cincinnati | Ohio | United States | ||
54 | Cleveland | Ohio | United States | ||
55 | Toledo | Ohio | United States | ||
56 | Allentown | Pennsylvania | United States | ||
57 | Erie | Pennsylvania | United States | ||
58 | Lancaster | Pennsylvania | United States | ||
59 | Philadelphia | Pennsylvania | United States | ||
60 | Pittsburgh | Pennsylvania | United States | ||
61 | Germantown | Tennessee | United States | ||
62 | Kingsport | Tennessee | United States | ||
63 | Nashville | Tennessee | United States | ||
64 | Austin | Texas | United States | ||
65 | Plano | Texas | United States | ||
66 | The Woodlands | Texas | United States | ||
67 | Burlington | Vermont | United States | ||
68 | Olympia | Washington | United States | ||
69 | Spokane | Washington | United States | ||
70 | Tacoma | Washington | United States | ||
71 | Madison | Wisconsin | United States | ||
72 | Milwaukee | Wisconsin | United States | ||
73 | Calgary | Alberta | Canada | ||
74 | Kingston | Ontario | Canada | ||
75 | Montreal | Quebec | Canada | ||
76 | Quebec City | Quebec | Canada | ||
77 | Trois-Rivieres | Quebec | Canada | ||
78 | Nantes | France |
Sponsors and Collaborators
- Medtronic
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DF4